The UK National Screening Committee has recommended targeted prostate cancer screening for a specific group of men: those aged 45 to 61 who carry a BRCA2 gene change and have a family history of breast, ovarian, pancreatic, or prostate cancer. This narrowly focused approach aims to catch aggressive cancers early while avoiding the harms of unnecessary testing in men at lower risk.

Why Prostate Screening Is So Complicated?

Prostate cancer screening sits at the center of one of medicine's trickiest dilemmas. Most prostate cancers grow slowly and may never cause harm, even if left untreated. When doctors detect these slow-growing tumors through screening, it's called overdiagnosis, and it can lead to unnecessary biopsies and treatments that carry serious side effects like loss of bladder control and erectile dysfunction.

The current PSA (prostate-specific antigen) test, which measures a protein produced by the prostate, isn't reliable enough for widespread screening. As many as 8 in 10 men who take a PSA test receive a false positive result, meaning the test suggests cancer when none is present. PSA levels can rise for many reasons unrelated to cancer, including benign prostate enlargement, recent ejaculation, infection, or vigorous exercise.

However, a subset of prostate cancers do grow quickly and require prompt treatment. Screening can help detect these aggressive cancers at an earlier stage, when treatment is more likely to work and save lives. This is why experts emphasize targeting screening toward men most likely to develop fast-growing prostate cancer.

Who Should Get Screened and Why?

The UK's final recommendation focuses exclusively on men with a BRCA2 gene change and relevant family history because research shows this group has a significantly higher risk of developing aggressive prostate cancer. The committee initially considered including men with BRCA1 gene changes, but newer evidence showed that men with BRCA2 mutations face a higher risk of fast-growing disease, while the same wasn't consistently shown for BRCA1 carriers.

Eligible men would be offered a PSA test every two years. By narrowing the screening population to those at highest risk, the approach reduces the harms of overdiagnosis while increasing the likelihood that screening will actually save lives.

What the Latest Real-World Data Shows?

Recent research presented at the American Society of Clinical Oncology conference examined how PSA screening relates to cancer detection in everyday medical practice. Researchers analyzed data from over 1.2 million men with prostate cancer diagnoses between 2018 and 2025, focusing on nearly 8,000 patients with sufficient medical records.

The findings were striking: patients who had received a PSA test in the three years before their diagnosis were significantly more likely to be diagnosed at an early stage compared to those without prior screening. Specifically, 42.8% of men with prior screening were diagnosed at early stages (stages I-II) versus 37.6% of men without screening.

This pattern held true across different age groups, even among men aged 70 and older, where routine screening is generally discouraged. Among men aged 55 to 69, the group for whom shared decision-making about screening is recommended, those with prior PSA screening were 43% more likely to be diagnosed at an early stage. For men 70 and older, the likelihood increased by 55%.

"Screening should only be introduced when the benefits outweigh the harms, including unnecessary and invasive overtreatment, and right now, the evidence is only strong enough to screen men aged 45 to 61 with BRCA2 gene changes and a relevant family history," explained Dr. Ian Walker, Cancer Research UK's Executive Director of Policy.

Dr. Ian Walker, Executive Director of Policy, Cancer Research UK

How to Determine If You're at Risk?

• BRCA Gene Testing: You can only know if you carry a BRCA1 or BRCA2 gene change through genetic testing. These changes are uncommon and typically only identified in people with a strong family history of cancer. If you're concerned about your risk, discuss it with your doctor.
• Family History Assessment: The screening recommendation applies to men with a family history of breast, ovarian, pancreatic, or prostate cancer. A strong family history is the key indicator for whether genetic testing might be appropriate for you.
• Age Range Consideration: The current recommendation targets men aged 45 to 61 with BRCA2 mutations and relevant family history. If you fall outside this age range or don't have a known BRCA2 change, discuss individual screening decisions with your healthcare provider based on your personal risk factors.
• Shared Decision-Making: For men without BRCA mutations but interested in screening, the American Cancer Society suggests discussions about PSA testing may begin at age 40 for those at higher risk, while the US Preventive Services Task Force recommends shared decision-making for men aged 55 to 69 years.

What About Men Without BRCA Mutations?

The UK committee recommended against prostate cancer screening for all men, Black men specifically, and men with only a family history but no BRCA2 variant. The evidence currently shows that screening these broader populations would expose too many men to the risks of overdiagnosis without providing enough benefit.

However, this doesn't mean screening is never appropriate for these groups. Research hasn't yet determined whether Black men or men with family history alone have higher risks of developing fast-growing prostate cancer, so it's unclear whether screening would cause more benefits than harms. The committee emphasized that more research into prostate cancer across diverse populations is needed to answer these questions.

Cancer Research UK has invested 28 million pounds over three years to find new and better ways to prevent, detect, and treat cancer, with ongoing studies examining screening approaches for men with BRCA1 mutations and genetic factors that influence prostate cancer risk.

The Bottom Line for Men's Health?

The shift toward targeted screening represents a more nuanced approach to prostate cancer detection. Rather than offering PSA tests to all men or avoiding screening altogether, the new recommendation focuses resources on those most likely to benefit. For men with a BRCA2 gene change and relevant family history, regular PSA screening every two years may help catch aggressive cancers early, when treatment is most effective.

For other men, the conversation about screening remains individualized. If you're concerned about prostate cancer risk, particularly if you have a strong family history of cancer, talk with your doctor about whether genetic testing or screening discussions are appropriate for your situation. The goal is to balance the real benefit of early detection with the very real risks of unnecessary testing and treatment.